Two Sigma Advisers
GRCE

Two Sigma Advisers’s Grace Therapeutics GRCE Stock Holding History

Two Sigma Advisers’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,067
Closed -$31K – 2735
2021
Q1 		$31K Sell
1,067
-4,906
-82% -$170K ﹤0.01% 2513
2020
Q4 		$93K Buy
5,973
+60
+1% +$693 ﹤0.01% 2277
2020
Q3 		$57K Sell
5,913
-1,679
-22% -$43.6K ﹤0.01% 2316
2020
Q2 		$171K Buy
7,592
+98
+1% +$2.86K ﹤0.01% 2285
2020
Q1 		$137K Buy
7,494
+244
+3% +$8.64K ﹤0.01% 2257
2019
Q4 		$853K Buy
7,250
+121
+2% +$12K ﹤0.01% 1651
2019
Q3 		$647K Buy
+7,129
New +$660K ﹤0.01% 1613

Other funds holding GRCE

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MMPW
Mitchell McLeod Pugh & Williams Mobile, Alabama $678M AUM 23.02% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $599M AUM 28.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers's GRCE Position: Q2 2021 in Review

Two Sigma Advisers sold out of Grace Therapeutics (GRCE) in Q2 2021, closing a stake of 1,067 shares — an estimated $31K sold.

Two Sigma Advisers first reported a position in GRCE in Q3 2019 and held it in 7 quarters. The position peaked at $853K in Q4 2019. 26 funds tracked by Wall St. Rank hold GRCE as of Q2 2021.

  • Two Sigma Advisers reported no remaining Grace Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Two Sigma Advisers sold 1,067 Grace Therapeutics shares in Q2 2021, an estimated $31K.
  • Two Sigma Advisers first reported a position in Grace Therapeutics in Q3 2019 and held it in 7 quarters.
  • Two Sigma Advisers's Grace Therapeutics position peaked at $853K in Q4 2019.
  • 26 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2021.

Based on Two Sigma Advisers's 13F filing for Q2 2021, filed 16 Aug 2021.